Tourmaline Bio Inc
NASDAQ:TRML

Watchlist Manager
Tourmaline Bio Inc Logo
Tourmaline Bio Inc
NASDAQ:TRML
Watchlist
Price: 47.98 USD Market Closed
Market Cap: 1.2B USD

Tourmaline Bio Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Tourmaline Bio Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Tourmaline Bio Inc
NASDAQ:TRML
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Tourmaline Bio Inc
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

Tourmaline Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Louisville, Kentucky and currently employs 129 full-time employees. The company went IPO on 2021-05-07. Tourmaline Bio, Inc., formerly Talaris Therapeutics, Inc., is a late-stage clinical biotechnology company. The firm is engaged in developing transformative medicines that improve the lives of patients with life-altering immune diseases. The Company’s lead program, TOUR006, is an anti-interleukin-6 (IL-6) antibody that exhibits differentiated properties, including high binding affinity to IL-6 and a naturally long half-life. TOUR006 selectively binds to IL-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. The firm focuses on developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional indications under consideration. TED is a debilitating autoimmune disorder. ASCVD is a group of disorders caused by plaque buildup and rupture in the artery walls and includes myocardial infarctions (heart attacks) and strokes.

TRML Intrinsic Value
Not Available

See Also

What is Tourmaline Bio Inc's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2024, Tourmaline Bio Inc's Revenue amounts to 0 USD.

Back to Top